Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Can Zepbound® (tirzepatide) be used in patients with gastroesophageal reflux disease (GERD)?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can Zepbound® (tirzepatide) be used in patients with gastroesophageal reflux disease (GERD)?

A preexisting condition of GERD was not a specific exclusion criterion for enrollment in the Zepbound clinical trials in adults with obesity or overweight.

US_cFAQ_TZPCWM311_COMORBID_GERD
US_cFAQ_TZPCWM311_COMORBID_GERDen-US

See important safety information, including boxed warning, in the attached prescribing information.

Prescribing Information Related to Gastroesophageal Reflux Disease

The use of tirzepatide has been associated with gastrointestinal adverse reactions, sometimes severe. Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.1

In the pooled data from two placebo-controlled trials for weight reduction (SURMOUNT-1 and SURMOUNT-2) gastroesophageal reflux disease (GERD) was reported in

  • 4% of participants treated with tirzepatide 5 mg
  • 4% of participants treated with tirzepatide 10 mg
  • 5% of participants with tirzepatide 15 mg
  • 2% of participants treated with placebo.1

Use in Patients With Preexisting GERD

Participants were excluded from clinical trials for weight management if they had a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or were chronically taking drugs that directly affect gastrointestinal motility.2-5

A preexisting condition of gastroesophageal reflux disease (GERD) was not a specific exclusion criterion for enrollment in the SURMOUNT clinical program in adults with obesity or overweight.

No additional information is available because Eli Lilly and Company has not sponsored a subgroup analysis of SURMOUNT study participants with a preexisting condition of GERD.

Lilly cannot provide clinical recommendations on the use of tirzepatide in patients with GERD. The treating physician may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors, in formulating an assessment and approach. The treating physician should consider potential risks and benefits of treatment options and monitor appropriately.

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

References

1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

2Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038

3Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X

4Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w

5Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945

Date of Last Review: November 20, 2024

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly